Gilead Stock Today

GILD -  USA Stock  

USD 71.38  0.69  0.96%

Gilead Sciences is trading at 71.38 as of the 27th of September 2021, a -0.96 percent decrease since the beginning of the trading day. The stock's lowest day price was 71.09. Gilead Sciences has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Gilead Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of March 2021 and ending today, the 27th of September 2021. Click here to learn more.
 Market Performance
6 of 100
  Odds Of Distress
Less than 2

Gilead Sciences Stock Profile

The next fiscal quarter end is expected on the 30th of September 2021. Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 13600 people. more on Gilead Sciences
Gilead Sciences is unlikely to experience financial distress in the next 2 years
Gilead Sciences has a strong financial position based on the latest SEC filings
Over 82.0% of the company shares are owned by institutional investors
Latest headline from www.nasdaq.com: Gilead Sciences, Inc. Ex-Dividend Date Scheduled for September 14, 2021 - Nasdaq
Gilead Sciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameGilead Sciences
Chairman and CEOJohn Martin  (View All)
Thematic Classifications
Active investing themes Gilead currently participates. (view all). An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Average Analyst Recommendation
Analysts covering Gilead Sciences report their recommendations after researching Gilead Sciences' financial statements, talking to executives and customers, or listening in on Gilead Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Gilead Sciences. The Gilead consensus assessment is calculated by taking the average forecast from all of the analysts covering Gilead Sciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Gilead Sciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Gilead Sciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 8 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.3 B1.3 B
Slightly Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.3 B1.3 B
Fairly Up
Decreasing
Slightly volatile
Net Cash Flow from Operations9.6 B8.2 B
Fairly Up
Increasing
Slightly volatile
Total Assets61.3 B68.4 B
Moderately Down
Increasing
Slightly volatile
Total Liabilities42.7 B50.2 B
Fairly Down
Increasing
Slightly volatile
Current Assets19.4 B16 B
Fairly Up
Increasing
Slightly volatile
Current Liabilities10.4 B11.4 B
Significantly Down
Increasing
Slightly volatile
Total Debt27.2 B31.4 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.00210.002
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.815
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.440.403
Significantly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Gilead Sciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Gilead Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Gilead Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Gilead Sciences' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Gilead Sciences' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
A- ( Average Bond Rating ) Very Good
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gilead Sciences' financial leverage. It provides some insight into what part of Gilead Sciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Gilead Sciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Gilead Sciences deploys its capital and how much of that capital is borrowed.
Liquidity
Gilead Sciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 30.18 B in liabilities with Debt to Equity (D/E) ratio of 1.53, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.33, which is within standard range for the sector.

Operating Cash Flow

9.64 BillionShare
Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 13,600 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 89.52 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Gilead Sciences conducts business under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.25 B outstanding shares of which 22.45 M shares are currently shorted by private and institutional investors with about 3.74 trading days to cover. Gilead Sciences currently holds about 6.84 B in cash with 9.09 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.46.
Check Gilead Sciences Probability Of Bankruptcy
Ownership
Gilead Sciences secures a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Gilead Ownership Details

Gilead Stock Price Odds Analysis

What are Gilead Sciences' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Gilead Sciences jumping above the current price in 90 days from now is about 19.45%. The Gilead Sciences probability density function shows the probability of Gilead Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Gilead Sciences has a beta of -0.2259. This usually indicates as returns on benchmark increase, returns on holding Gilead Sciences are expected to decrease at a much lower rate. During the bear market, however, Gilead Sciences is likely to outperform the market. Additionally, the company has an alpha of 0.0899, implying that it can generate a 0.0899 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 71.38HorizonTargetOdds Up 71.38 
80.24%90 days
 71.38 
19.45%
Based on a normal probability distribution, the odds of Gilead Sciences to move above the current price in 90 days from now is about 19.45 (This Gilead Sciences probability density function shows the probability of Gilead Stock to fall within a particular range of prices over 90 days) .

Gilead Sciences Historical Income Statement

Gilead Sciences Income Statement is one of the three primary financial statements used for reporting Gilead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Gilead Sciences revenue and expense. Gilead Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Gilead Sciences Earning Before Interest and Taxes EBIT is projected to increase significantly based on the last few years of reporting. The past year's Earning Before Interest and Taxes EBIT was at 2.69 Billion. The current year Net Income is expected to grow to about 126.2 M, whereas Cost of Revenue is forecasted to decline to about 4.5 B. View More Fundamentals

Gilead Stock Against Markets

Picking the right benchmark for Gilead Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Gilead Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Gilead Sciences is critical whether you are bullish or bearish towards Gilead Sciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Gilead Sciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Gilead Sciences Corporate Directors

Gilead Sciences corporate directors refer to members of a Gilead Sciences board of directors. The board of directors generally takes responsibility for the Gilead Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Gilead Sciences' board members must vote for the resolution. The Gilead Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Gayle Wilson - Independent DirectorProfile
Jacqueline Barton - DirectorProfile
John Madigan - Independent DirectorProfile
Kevin Lofton - Independent DirectorProfile
Please check Risk vs Return Analysis. Note that the Gilead Sciences information on this page should be used as a complementary analysis to other Gilead Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Gilead Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.